Michael Pourdehnad, Senior Vice President, Head of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb, shared a post on LinkedIn:
“Early clinical development is where scientific promise is truly tested and where smart partnerships can make the biggest difference. This strategic collaboration between Bristol Myers Squibb and Hengrui Pharma reflects a shared commitment to accelerating early clinical learning, establishing proof of concept with rigor, and making disciplined decisions at the right moment in development.
Drawing on distinct strengths across regions will allow us to move promising programs through early development with greater speed, efficiency, and scientific confidence—helping ensure that only the most compelling opportunities advance for patients.
I’m proud of the teams at BMS driving this work every day, and of how this collaboration strengthens our approach to early clinical development.
Read here.”
Other articles about Bristol Myers Squibb and Hengrui Pharma on OncoDaily.